Cytek Grows with New Tech and Strong Revenue | Business and Finance News

Cytek Biosciences delivers strong Q2 earnings with $48.1M in revenue, up 6% YoY, fueled by explosive growth in U.S. and China markets—especially their FSP instruments and services. Europe lags due to budget constraints, but new tech like the 60-color Borealis flow cytometer and automated Aurora Evo are winning early praise, boosting lab efficiency. The company raises its full-year revenue forecast to $207M–$212M, betting on recurring revenue, expanding installed base, and growing cloud platform adoption—all driving profitable, integrated growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/af0905b30a4b0b87